SAHA (vorinostat) facilitates functional polymer-based gene transfection via upregulation of ROS and synergizes with TRAIL gene delivery for cancer therapy

References

• Cheng CJ, Bahal R, Babar IA, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 2015;5;518:107–110.
   Web of Science ®Google Scholar
• Ginn SL, Alexander IE, Edelstein ML, et al. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med. 2013;15:65–77.
   PubMed Web of Science ®Google Scholar
• Song ES, Lee V, Surh CD, et al. Antigen presentation in retroviral vector-mediated gene transfer in vivo. Proc Natl Acad Sci USA. 1997;94:1943–1948.
   PubMed Web of Science ®Google Scholar
• Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature 1997;389:239–242.
   PubMed Web of Science ®Google Scholar
• Pack DW, Hoffman AS, Pun S, et al. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005;4:581–593.
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15:541–555.
   PubMed Web of Science ®Google Scholar
• Schaffer DV, Fidelman NA, Dan N, et al. Vector unpacking as a potential barrier for receptor-mediated polyplex gene delivery. Biotechnol Bioeng. 2000;67:598–606.
   PubMed Web of Science ®Google Scholar
• Bishop CJ, Kozielski KL, Green JJ. Exploring the role of polymer structure on intracellular nucleic acid delivery via polymeric nanoparticles. J Control Release. 2015;219:488–499.
   PubMed Web of Science ®Google Scholar
• Ko J, Park K, Kim YS, et al. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy. J Control Release. 2007;123:109–115.
   PubMed Web of Science ®Google Scholar
• Kost J, Langer R. Responsive polymeric delivery systems. Adv Drug Deliv Rev. 2012;64:327–341.
   Web of Science ®Google Scholar
• Li P, Liu DH, Miao L, et al. A pH-sensitive multifunctional gene carrier assembled via layer-by-layer technique for efficient gene delivery. Int J Nanomed. 2012;7:925–939.
   PubMed Web of Science ®Google Scholar
• Shim MS, Xia Y. A reactive oxygen species (ROS)-responsive polymer for safe, efficient, and targeted gene delivery in cancer cells. Angew Chem Int Ed. 2013;52:6926–6929.
   PubMed Web of Science ®Google Scholar
• Luo K, He B, Wu Y, et al. Functional and biodegradable dendritic macromolecules with controlled architectures as nontoxic and efficient nanoscale gene vectors. Biotechnol Adv. 2014;32:818–830.
   PubMed Web of Science ®Google Scholar
• Liu X, Xiang JJ, Zhu DC, et al. Fusogenic reactive oxygen species triggered charge-reversal vector for effective gene delivery. Adv Mater. 2016;2;28:1743–1752.
   Web of Science ®Google Scholar
• Schumacker PT. Reactive oxygen species in cancer: a dance with the devil. Cancer Cell. 2015;27:156–157.
   PubMed Web of Science ®Google Scholar
• Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13:673–691.
   PubMed Web of Science ®Google Scholar
• Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug [Article]. Nat Biotechnol. 2007;25:84–90.
   PubMed Web of Science ®Google Scholar
• Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008;269:7–17.
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541–5552.
   PubMed Web of Science ®Google Scholar
• Li C, Hu J, Li W, et al. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment. Biomater Sci. 2017;5:77–88.
   Web of Science ®Google Scholar
• Zhou Z, Liu X, Zhu D, et al. Nonviral cancer gene therapy: delivery cascade and vector nanoproperty integration. Adv Drug Deliv Rev. 2017;115:115–154.
   PubMed Web of Science ®Google Scholar
• Zabner J, Fasbender AJ, Moninger T, et al. Cellular and Molecular Barriers to gene transfer by a cationic lipid. J Biol Chem. 1995;270:18997–19007.
   PubMed Web of Science ®Google Scholar
• Khalil IA, Kogure K, Akita H, et al. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev. 2006;58:32–45.
   PubMed Web of Science ®Google Scholar
• Luo K, Li C, Li L, et al. Arginine functionalized peptide dendrimers as potential gene delivery vehicles. Biomaterials 2012;33:4917–4927.
   PubMed Web of Science ®Google Scholar
• Qiu N, Liu X, Zhong Y, et al. Esterase-activated charge-reversal polymer for fibroblast-exempt cancer gene therapy. Adv Mater. 2016;28:10578–10622.
   Web of Science ®Google Scholar
• Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov. 2009;8:579–591.
   PubMed Web of Science ®Google Scholar
• Joris F, De Smedt SC, Raemdonck K. Small molecules convey big messages: boosting non-viral nucleic acid delivery with low molecular weight drugs. Nano Today. 2017;16:14–29.
   Web of Science ®Google Scholar
• Fraley R, Straubinger RM, Rule G, et al. Liposome-mediated delivery of deoxyribonucleic acid to cells: enhanced efficiency of delivery related to lipid composition and incubation conditions. Biochemistry-Us 1981;20:6978–6987.
   PubMed Web of Science ®Google Scholar
• Yu HJ, Zou YL, Wang YG, et al. Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery. Acs Nano. 2011;5:9246–9255.
   PubMed Web of Science ®Google Scholar
• Weng A, Manunta MDI, Thakur M, et al. Improved intracellular delivery of peptide- and lipid-nanoplexes by natural glycosides. J Control Release. 2015;206:75–90.
   PubMed Web of Science ®Google Scholar
• Ming X, Carver K, Fisher M, et al. The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. Nucleic Acids Res. 2013;41:3673–3687.
   PubMed Web of Science ®Google Scholar
• Nair RR, Rodgers JR, Schwarz LA. Enhancement of transgene expression by combining glucocorticoids and anti-mitotic agents during transient transfection using DNA-cationic liposomes. Mol Therapy. 2002;5:455–462.
   PubMed Web of Science ®Google Scholar
• Vaughan EE, Dean DA. Intracellular trafficking of plasmids during transfection is mediated by microtubules. Mol Therapy. 2006;13:422–428.
   PubMed Web of Science ®Google Scholar
• Zhou X, Liu X, Zhao B, et al. Jumping the nuclear envelop barrier: Improving polyplex-mediated gene transfection efficiency by a selective CDK1 inhibitor RO-3306. J Control Release. 2016;234:90–97.
   PubMed Web of Science ®Google Scholar
• Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2005;102:673–678.
   PubMed Web of Science ®Google Scholar
• Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998;10:559–563.
   PubMed Web of Science ®Google Scholar
• French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med. 1999;5:146–147.
   PubMed Web of Science ®Google Scholar
• Jiang H, Wang S, Zhou X, et al. New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment. J Control Release. 2018;286:254–263.
   PubMed Web of Science ®Google Scholar
• de Miguel D, Lemke J, Anel A, et al. Onto better TRAILs for cancer treatment [Review]. Cell Death Differ. 2016;23:733–747.
   PubMed Web of Science ®Google Scholar
• Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 2001;7:383–385.
   PubMed Web of Science ®Google Scholar
• von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy [Review]. Nat Rev Cancer. 2017;17:352–366.
   PubMed Web of Science ®Google Scholar
• Maksimovic-Ivanic D, Stosic-Grujicic S, Nicoletti F, et al. Resistance to TRAIL and how to surmount it. Immunol Res. 2012;52:157–168.
   PubMed Web of Science ®Google Scholar
• Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther. 2012;11:3–13.
   PubMed Web of Science ®Google Scholar
• Carlisi D, Lauricella M, D’Anneo A, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer. 2009;45:2425–2438.
   PubMed Web of Science ®Google Scholar
• Butler LM, Liapis V, Bouralexis S, et al. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer. 2006;119:944–954.
   PubMed Web of Science ®Google Scholar